Analyst Price Target is $22.25
▲ +1,723.77% Upside Potential
This price target is based on 7 analysts offering 12 month price targets for Aclaris Therapeutics in the last 3 months. The average price target is $22.25, with a high forecast of $38.00 and a low forecast of $9.00. The average price target represents a 1,723.77% upside from the last price of $1.22.
Current Consensus is
Hold
The current consensus among 7 contributing investment analysts is to hold stock in Aclaris Therapeutics. This Hold consensus rating has held steady for over two years.
Aclaris Therapeutics, Inc. a clinical-stage biopharmaceutical company, engages in the development of novel drug candidates for immune-inflammatory diseases in the United States. The company operates through two segments, Therapeutics and Contract Research. The Therapeutics segment is involved in identifying and developing therapies to address significant unmet needs for immuno-inflammatory diseases. The Contract Research segment provides laboratory services. It develops Zunsemetinib (ATI-450), an MK2 inhibitor which is under Phase 1b/2 trials for the treatment of metastatic breast and pancreatic cancer; ATI-1777, a soft JAK 1/3 inhibitor, completed Phase 2b trails for the treatment of moderate to severe atopic dermatitis and other dermatologic conditions; and ATI-2138, an oral covalent inhibitor of ITK and JAK3 inhibitor under Phase 1 trials as a treatment for T cell-mediated autoimmune diseases. The company was incorporated in 2012 and is headquartered in Wayne, Pennsylvania.
Read More
